1. Search Result
Search Result
Results for "

neck

" in MedChemExpress (MCE) Product Catalog:

66

Inhibitors & Agonists

4

Biochemical Assay Reagents

7

Peptides

1

MCE Kits

11

Inhibitory Antibodies

7

Natural
Products

5

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-B0192A
    Alfuzosin hydrochloride
    1 Publications Verification

    SL 77499-10

    Adrenergic Receptor Endocrinology
    Alfuzosin (SL 77499-10) hydrochloride is an orally active, selective and competitive α1-adrenoceptor antagonist. Alfuzosin hydrochloride relaxes the muscles of the prostate and bladder neck, aiding in urination. Alfuzosin hydrochloride can be used in study of benign prostatic hyperplasia (BPH) .
    Alfuzosin hydrochloride
  • HY-B0192
    Alfuzosin
    1 Publications Verification

    SL 77499

    Adrenergic Receptor Endocrinology
    Alfuzosin (SL 77499-10) is an orally active, selective and competitive α1-adrenoceptor antagonist. Alfuzosin relaxes the muscles of the prostate and bladder neck, aiding in urination. Alfuzosin can be used in study of benign prostatic hyperplasia (BPH) .
    Alfuzosin
  • HY-P99461

    ISU-104

    EGFR Cancer
    Barecetamab (ISU-104) is a fully human anti-ErbB3 monoclonal antibody. Barecetamab can be used for the research of recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) .
    Barecetamab
  • HY-16488
    Temoporfin
    5+ Cited Publications

    m-THPC; KW2345

    Reactive Oxygen Species Cancer
    Temoporfin (m-THPC), a reduced porphyrin, is a potent second-generation photosensitizer. Temoporfin can be used in the research of photodynamic therapy (PDT) for head and neck cancers .
    Temoporfin
  • HY-113168
    Butyrylcarnitine
    1 Publications Verification

    Endogenous Metabolite Cardiovascular Disease Metabolic Disease Cancer
    Butyrylcarnitine is an endogenous metabolite found in plasma. Elevated levels of Butyrylcarnitine are closely associated with abnormalities in lipid and energy metabolism. Butyrylcarnitine can serve as a diagnostic and prognostic indicator for certain diseases, such as heart failure and head and neck cancer .
    Butyrylcarnitine
  • HY-P99208
    Lirilumab
    2 Publications Verification

    IPH2102

    Transmembrane Glycoprotein Cancer
    Lirilumab (IPH2102) is an anti-KIR monoclonal antibody, and shows antitumor activity. Lirilumab can be used in Leukemia, squamous cell carcinoma of the head and neck (SCCHN) research .
    Lirilumab
  • HY-169581

    Reactive Oxygen Species Mitosis Cancer
    DIM-C-pPhtBu is an orally active endoplasmic reticulum stress activator. DIM-C-pPhtBu induces mitochondrial and lysosome dysfunction, excessive mitosis, ROS production, and unfolded protein response-mediated cell death in neck cancer cells. DIM-C-pPhtBu has antitumor activity .
    DIM-C-pPhtBu
  • HY-155645

    Topoisomerase Apoptosis Cancer
    Topoisomerase II inhibitor 15 (compound 2g) is a Topoisomerase II inhibitor. Topoisomerase II inhibitor 15 potently is an apoptotic inducer with greater selectivity against head and neck tumors .
    Topoisomerase II inhibitor 15
  • HY-B0192AR

    Adrenergic Receptor Endocrinology
    Alfuzosin (hydrochloride) (Standard) is the analytical standard of Alfuzosin (hydrochloride). This product is intended for research and analytical applications. Alfuzosin (SL 77499-10) hydrochloride is an orally active, selective and competitive α1-adrenoceptor antagonist. Alfuzosin hydrochloride relaxes the muscles of the prostate and bladder neck, aiding in urination. Alfuzosin hydrochloride can be used in study of benign prostatic hyperplasia (BPH) .
    Alfuzosin hydrochloride (Standard)
  • HY-P99500

    RM-1929; Cetuximab-IRDye-700DX

    EGFR Cancer
    Cetuximab sarotalocan (RM-1929) is an IRdye700DX (near-infrared photosensitizing dye) conjugate of Cetuximab (anti-EGFR monoclonal antibody). Cetuximab sarotalocan can be used for head and neck cancers research .
    Cetuximab sarotalocan
  • HY-126425

    Parasite Infection
    NCGC00262650 is a potent apical membrane antigen 1-rhoptry neck protein 2 (AMA1-RON2) interaction inhibitor. NCGC00262650 can block entry of merozoites into red blood cells with an IC50 of 9.8 μM .
    NCGC00262650
  • HY-169730

    Wnt Cancer
    Wnt pathway inhibitor 5 (Compound 28) is wnt pathway inhibitor, with an IC50 value of < 0.003 μΜ. Wnt pathway inhibitor 5 inhibits many cancers, including ovarian teratocarcinoma cancer, breast cancer, osteosarcoma, head and neck squamous carcinoma .
    Wnt pathway inhibitor 5
  • HY-170843

    Apoptosis Cancer
    Antitumor agent-198 (Compound A3) exhibits cytotoxicity in head and neck squamous cell carcinoma (HNSCC) cells, that inhibits the proliferation of CAL27, HN6, HN30, SCC9 and SCC25 with IC50 of 4 nM-77 nM. Antitumor agent-198 inhibits the HNSCC cell migration, arrests the cell cycle, and induces apoptosis .
    Antitumor agent-198
  • HY-P99406

    MCLA 158

    EGFR Cancer
    Petosemtamab (MCLA 158) is an anti- EGFR (Kd: 0.22 nM) and anti-LGR5 (Kd: 0.86 nM) monoclonal antibody (mAb). Petosemtamab leads to EGFR signaling blockade and receptor degradation in LGR5+ cancer cells. Petosemtamab can be used in the research of solid tumors, such as head and neck squamous cell carcinoma (HNSCC), metastatic colorectal cancer (CRC) .
    Petosemtamab
  • HY-N14752

    Antibiotic Bacterial Infection Cancer
    Hydroxymycotrienin A is an Ansa antibiotic. Hydroxymycotrienin A has the activity of inhibiting human neck tumor cell line, and its inhibitory effect on human papillomavirus (HPV) gene positive neck tumor cells (such as HeLa, CaSKi, SiHa, etc.) is stronger than HPV gene negative cells .
    Hydroxymycotrienin A
  • HY-N15103

    Antibiotic Bacterial Infection Cancer
    Hydroxymycotrienin B is an Ansa antibiotic. Hydroxymycotrienin B has the activity of inhibiting human neck tumor cell line, and its inhibitory effect on human papillomavirus (HPV) gene positive neck tumor cells (such as HeLa, CaSKi, SiHa, etc.) is stronger than HPV gene negative cells .
    Hydroxymycotrienin B
  • HY-P99032
    Monalizumab
    3 Publications Verification

    IPH2201

    Checkpoint Kinase (Chk) IFNAR Inflammation/Immunology Cancer
    Monalizumab (IPH2201) is an immune checkpoint inhibitor targeting Natural Killer Group 2A (NKG2A). Monalizumab, a humanized anti-NKG2A blocking mAb, increases IFN-γ production, thereby promoting NK cell effector functions. Monalizumab can be used for the research of head and neck squamous cell carcinoma (HNSCC) .
    Monalizumab
  • HY-147802

    EGFR Apoptosis Cancer
    EGFR-IN-59 (Compound 8c) is a EGFR inhibitor (IC50=190 nM) and apoptosis inducer. EGFR-IN-59 exhibits cytotoxicity against non-small lung cancer cell lines (A549) and normal lung fibroblasts (WI38) with IC50s of 8.62 and 52.6 µM, respectively. EGFR-IN-59 can be used for the research of various cancers such as non-small cell lung cancer (NSCLC), head and neck cancer, breast cancer and colorectal cancer .
    EGFR-IN-59
  • HY-148751

    TRP Channel Cancer
    TRPV1 activator-1 (compound 8), a capsaicin analog, has an altered neck structure. TRPV1 activator-1 interacts specifically with T551 residue .
    TRPV1 activator-1
  • HY-108345

    Antibiotic Cancer
    Bleomycin is a glycopeptide antibiotic. Bleomycin has potent antitumour activities against a range of lymphomas, head and neck cancers and germ-cell tumours. Bleomycin can be used for the research of cancer and chemotherapy .
    Bleomycin
  • HY-16349
    Nimorazole
    1 Publications Verification

    K-1900

    Parasite Antibiotic Infection Cancer
    Nimorazole (K-1900), a 2-nitroimidazole, is a hypoxic cell-radiation sensitizer. Nimorazole has anti-infective and anti-protozoal against trichomoniasis. Nimorazole has the potential for head and neck cancer .
    Nimorazole
  • HY-B1833

    HQ-495

    GABA Receptor Neurological Disease
    Afloqualone (HQ-495) is an orally active central muscle relaxant and antivertiginous agent that can increase the sensitivity of GABA receptors in neurons of the lateral vestibular nucleus. Afloqualone (HQ-495) can be used in the research of low back pain and neck-arm-shoulder syndrome .
    Afloqualone
  • HY-16349R

    Parasite Antibiotic Infection Cancer
    Nimorazole (Standard) is the analytical standard of Nimorazole. This product is intended for research and analytical applications. Nimorazole (K-1900), a 2-nitroimidazole, is a hypoxic cell-radiation sensitizer. Nimorazole has anti-infective and anti-protozoal against trichomoniasis. Nimorazole has the potential for head and neck cancer .
    Nimorazole (Standard)
  • HY-NP164

    Con A-HRP

    Fluorescent Dye Cancer
    Concanavalin A-HRP (Con A-HRP) is a HRP-labled Concanavalin A (HY-P2149). Concanavalin A is a Ca 2+/Mn 2+-dependent and mannose/glucose-binding plant lectin. Concanavalin A binds the N- and O-glycosylated proteins of head and neck carcinoma cells glycoproteins .
    Concanavalin A-HRP
  • HY-152007S

    Isotope-Labeled Compounds Endogenous Metabolite Cardiovascular Disease Metabolic Disease Cancer
    Butyrylcarnitine-d3 hydrochloride is deuterium labeled Butyrylcarnitine (HY-113168). Butyrylcarnitine is an endogenous metabolite found in plasma. Elevated levels of Butyrylcarnitine are closely associated with abnormalities in lipid and energy metabolism. Butyrylcarnitine can serve as a diagnostic and prognostic indicator for certain diseases, such as heart failure and head and neck cancer .
    Butyrylcarnitine-d3 hydrochloride
  • HY-113168R

    Reference Standards Endogenous Metabolite Cardiovascular Disease Metabolic Disease Cancer
    Butyrylcarnitine (Standard) is the analytical standard of Butyrylcarnitine (HY-113168). This product is intended for research and analytical applications. Butyrylcarnitine is an endogenous metabolite found in plasma. Elevated levels of Butyrylcarnitine are closely associated with abnormalities in lipid and energy metabolism. Butyrylcarnitine can serve as a diagnostic and prognostic indicator for certain diseases, such as heart failure and head and neck cancer .
    Butyrylcarnitine (Standard)
  • HY-144614

    DYRK Apoptosis Neurological Disease Cancer
    JH-XVII-10 is a potent, selective and orally active DYRK1A and DYRK1B inhibitor with IC50s of 3 nM and 5 nM for DYRK1A and DYRK1B, respectively. JH-XVII-10 shows antitumor efficacy in neck squamous cell carcinoma (HNSCC) cell lines .
    JH-XVII-10
  • HY-B0192S

    SL 77499-d7

    Adrenergic Receptor Endocrinology
    Alfuzosin-d7 is the deuterium labeled Alfuzosin . Alfuzosin (SL 77499-10) is an orally active, selective and competitive α1-adrenoceptor antagonist. Alfuzosin relaxes the muscles of the prostate and bladder neck, aiding in urination. Alfuzosin can be used in study of benign prostatic hyperplasia (BPH) .
    Alfuzosin-d7
  • HY-NP164B

    Con A-AF488

    Fluorescent Dye Cancer
    Concanavalin A-AF488 (Con A-AF488) is an AF488-labled Concanavalin A (HY-P2149). Concanavalin A is a Ca 2+/Mn 2+-dependent and mannose/glucose-binding plant lectin. Concanavalin A binds the N- and O-glycosylated proteins of head and neck carcinoma cells glycoproteins .
    Concanavalin A-AF488
  • HY-13617

    CGP 30694

    Antifolate Cancer
    Edatrexate (CGP 30694), as known as 10-Ethyl-10-deazaaminopterin, is Methotrexate (HY-14519) analog, exhibits antitumor activity against MTX-resistant tumors. Edatrexate is an antifolate antimetabolite, can be used for reasearch of non-small-cell lung cancer, breast cancer, non-Hodgkin's lymphoma, and cancer of the head and neck .
    Edatrexate
  • HY-P991061

    SRF-114

    CCR Cancer
    CHS-114 (SRF-114) is a fully human IgG1 antibody that targets CCR8. CHS-114 has the potential for the study of head and neck squamous cell carcinoma (HNSCC). The isotype control for CHS-114 can refer to Human IgG1 kappa, Isotype Control (HY-P99001) .
    CHS-114
  • HY-P991244

    EGFR Cancer
    REGN-1400 is a humanized monoclonal antibody inhibitor targeting ErbB3. REGN-1400 reduces tumor cell proliferation by inhibiting ErbB3 and blocking related signaling pathways. REGN-1400 is promising for research of solid tumors such as non-small cell lung cancer (NSCLC), colorectal cancer (CRC), and squamous cell carcinoma of the head and neck (SCCHN) .
    REGN-1400
  • HY-132259

    ABT-414

    Antibody-Drug Conjugates (ADCs) EGFR Cancer
    Depatuxizumab mafodotin (ABT-414) is an antibody-drug conjugate (ADC). Depatuxizumab mafodotin specifically targets the epidermal growth factor receptor (EGFR). Depatuxizumab mafodotin can be used in the study of glioma, head and neck squamous cell carcinoma, non-small cell lung cancer, epidermoid carcinoma of the skin, and squamous cell carcinoma of the tongue .
    Depatuxizumab mafodotin
  • HY-P1016

    Endothelin Receptor Cardiovascular Disease
    BQ-3020 is a selective endothelin receptor (ETB receptor) agonist that displaces [ 125I] ET-1 binding to ETB receptors, with an IC50 value of 0.2 nM. BQ-3020 elicits vasoconstriction in the rabbit pulmonary artery. BQ-3020 makes relaxation of the pig urinary bladder neck and can be used for cardiovascular disease research 1 2.
    BQ-3020
  • HY-B1833R

    GABA Receptor Neurological Disease
    Afloqualone (Standard) is the analytical standard of Afloqualone. This product is intended for research and analytical applications. Afloqualone (HQ-495) is an orally active central muscle relaxant and antivertiginous agent that can increase the sensitivity of GABA receptors in neurons of the lateral vestibular nucleus. Afloqualone (HQ-495) can be used in the research of low back pain and neck-arm-shoulder syndrome .
    Afloqualone (Standard)
  • HY-15673
    KP372-1
    2 Publications Verification

    Quinone Reductase Akt Reactive Oxygen Species Apoptosis Cancer
    KP372-1 is an Akt inhibitor that inhibits proliferation and induces apoptosis and anoikis. KP372-1 is also an NQO1 redox cycling agent that causes DNA damage (including DNA breakage) by generating ROS. KP372-1 can be used in cancer research (such as head and neck squamous cell carcinoma (HNSCC) and pancreatic cancer) .
    KP372-1
  • HY-13334
    BGT226 maleate
    5+ Cited Publications

    NVP-BGT226 maleate

    PI3K mTOR Autophagy Apoptosis Cancer
    BGT226 (NVP-BGT226 maleate) is a PI3K (with IC50s of 4 nM, 63 nM and 38 nM for PI3Kα, PI3Kβ and PI3Kγ) /mTOR dual inhibitor which displays potent growth-inhibitory activity against human head and neck cancer cells .
    BGT226 maleate
  • HY-B0192S3

    SL 77499-d6

    Isotope-Labeled Compounds Adrenergic Receptor Endocrinology
    Alfuzosin-d6 (SL 77499-d6) is deuterium labeled Alfuzosin. Alfuzosin (SL 77499-10) is an orally active, selective and competitive α1-adrenoceptor antagonist. Alfuzosin relaxes the muscles of the prostate and bladder neck, aiding in urination. Alfuzosin can be used in study of benign prostatic hyperplasia (BPH) .
    Alfuzosin-d6
  • HY-13334A
    BGT226
    5+ Cited Publications

    NVP-BGT226

    PI3K mTOR Autophagy Cancer
    BGT226 (NVP-BGT226) is a PI3K (with IC50s of 4 nM, 63 nM and 38 nM for PI3Kα, PI3Kβ and PI3Kγ)/mTOR dual inhibitor which displays potent growth-inhibitory activity against human head and neck cancer cells .
    BGT226
  • HY-B0192S3A

    SL 77499-10-d6

    Isotope-Labeled Compounds Adrenergic Receptor Endocrinology
    Alfuzosin (hydrochloride)-d6 (SL 77499-10-d6) is deuterium labeled Alfuzosin (hydrochloride). Alfuzosin (SL 77499-10) hydrochloride is an orally active, selective and competitive α1-adrenoceptor antagonist. Alfuzosin hydrochloride relaxes the muscles of the prostate and bladder neck, aiding in urination. Alfuzosin hydrochloride can be used in study of benign prostatic hyperplasia (BPH) .
    Alfuzosin hydrochloride-d6
  • HY-144617

    DYRK Cancer
    JH-XIV-68-3 is a selective macrocyclic inhibitor of DYRK1A/B. JH-XIV-68-3 displays selectivity for DYRK1A and close family member DYRK1B in biochemical and cellular assays. JH-XIV-68-3 demonstrates antitumor efficacy in head and neck squamous cell carcinoma (HNSCC) cell lines .
    JH-XIV-68-3
  • HY-169135

    PROTACs Proteasome Cancer
    PROTAC 20S proteasome subunit β5 degrader 2 is a PROTAC degrader for 20S proteasome subunit β5, with a DC50 of 0.16 μM. PROTAC 20S proteasome subunit β5 degrader 2 inhibits the proliferation of cancer cell FaDu with IC50 of 0.23 μM. PROTAC 20S proteasome subunit β5 degrader 2 exhibits antitumor efficacy in mice models . (Pink: Ligand for target protein (HY-10227); Blue: Ligand for E3 ligase (HY-103596); Black: Linker (HY-Y1760))
    PROTAC 20S proteasome subunit β5 degrader 2
  • HY-100218A
    RSL3
    Maximum Cited Publications
    303 Publications Verification

    (1S,3R)-RSL3

    p62 Glutathione Peroxidase Ferroptosis Reactive Oxygen Species Cancer
    RSL3 ((1S,3R)-RSL3) is an inhibitor of glutathione peroxidase 4 (GPX4) (ferroptosis activator), reduces the expression of GPX4 protein, and induces ferroptotic death of head and neck cancer cell. RSL3 increases the expression of p62 and Nrf2 and inactivates Keap1 in HN3-rslR cells .
    RSL3
  • HY-B1833S

    HQ-495-d7

    Isotope-Labeled Compounds GABA Receptor Neurological Disease
    Afloqualone-d7 (HQ-495-d7) is deuterium labeled Afloqualone. Afloqualone (HQ-495) is an orally active central muscle relaxant and antivertiginous agent that can increase the sensitivity of GABA receptors in neurons of the lateral vestibular nucleus. Afloqualone (HQ-495) can be used in the research of low back pain and neck-arm-shoulder syndrome .
    Afloqualone-d7
  • HY-E70188

    EC:3.1.6.4; GALNS

    Biochemical Assay Reagents Cancer
    N-Acetylgalactosamine-6-Sulfatase (GALNS) is a potential general biomarker for multiple malignancies (such as lung cancer, breast cancer, head and neck cancer, etc.). N-Acetylgalactosamine-6-Sulfatase deficiency causes mucopolysaccharidosis type IVA (MPS IVA), also known as Morquio A syndrome. N-Acetylgalactosamine-6-Sulfatase can be used in MPS IVA as well as cancer research .
    N-Acetylgalactosamine-6-Sulfatase
  • HY-NP164A

    Con A-Cy5.5

    Fluorescent Dye Cancer
    Concanavalin A-Cy5.5 (Con A-Cy5.5) is a Cy5.5 (HY-D0924)-labled Concanavalin A (HY-P2149). Concanavalin A is a Ca 2+/Mn 2+-dependent and mannose/glucose-binding plant lectin. Concanavalin A binds the N- and O-glycosylated proteins of head and neck carcinoma cells glycoproteins .
    Concanavalin A-Cy5.5
  • HY-P1016B

    Endothelin Receptor Cardiovascular Disease
    BQ-3020 ammonium is a selective endothelin receptor (ETB receptor) agonist. BQ-3020 ammonium inhibits [ 125I] ET-1 binding to ETB receptors, with an IC50 value of 0.2 nM. BQ-3020 ammonium elicits vasoconstriction in the rabbit pulmonary artery. BQ-3020 ammonium makes relaxation of the pig urinary bladder neck and can be used for cardiovascular disease research . .
    BQ-3020 ammonium
  • HY-148664

    Eukaryotic Initiation Factor (eIF) Cancer
    eIF4E-IN-4 (Compound 33) is a selective inhibitor of eukaryotic initiation factor 4E (eIF4E) with biochemical activity value of 95 nM. eIF4E-IN-4 inhibits cap-dependent mRNA translation with an IC50 value of 2.5 μM. eIF4E-IN-4 can be used for breast cancer, colon cancer, and head and neck cancer study .
    eIF4E-IN-4
  • HY-162713

    EGFR PI3K PPAR Cancer
    MTX-531 is an oral drug that inhibits EGFR (with an IC50 of 14.7 nM) and PI3K (with IC50 values of 6.4, 233, 8.3, and 1.1 nM for PI3Kα, PI3Kβ, PI3Kγ, and PI3Kδ respectively), and it has anti-tumor effects. MTX-531 also acts as a weak agonist of PPARγ, with an IC50 of 2.5 µM, helping to alleviate hyperglycemia induced by PI3K inhibitors .
    MTX-531
  • HY-134545

    NALA

    Reactive Oxygen Species Cancer
    N-Arachidonoyl-L-alanine is an endocannabinoid analog with anti-cancer effects. N- Arachidonoyl-L-alanine kills HNSCC cells through 5-LO-mediated ROS productio .
    N-Arachidonoyl-L-alanine

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: